Article

Thermal proteome profiling of breast cancer cells reveals proteasomal activation by CDK4/6 inhibitor palbociclib

2017-10-13

Abstract excerpt

Palbociclib is a CDK4/6 inhibitor approved for metastatic estrogen receptor positive breast cancer. In addition to G1 cell cycle arrest, palbociclib treatment results in cell senescence, a phenotype that are not readily explained by CDK4/6 inhibition. In order to identify a molecular mechanism responsible for palbociclib-induced senescence, we performed thermal proteome profiling of MCF7 breast cancer cells. In ad...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 45f5e933-9984-5b74-8f97-21c0aabca8e0
DOI: 10.1101/202770

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Thermal proteome profiling of breast cancer cells reveals proteasomal activation by CDK4/6 inhibitor palbociclibDOI 10.1101/202770Read

Thermal proteome profiling of breast cancer cells reveals proteasomal activation by CDK4/6 inhibitor palbociclib.Semantic proximity Read

Proteasome dysregulation in human cancer: implications for clinical therapiesSemantic proximity Read

Expression and DNA methylation of 20S proteasome subunits as prognostic and resistance markers in cancerSemantic proximity Read

Chemoproteomic Evaluation of Target Engagement by the Cyclin-Dependent Kinase 4 and 6 Inhibitor Palbociclib Correlates with Cancer Cell ResponseSemantic proximity Read

Pharmacological CDK4/6 inhibition promotes vulnerability to lysosomotropic agents in breast cancerSemantic proximity Read

Rational design of HER2-targeted combination therapies to reverse drug resistance in fibroblast-protected HER2+ breast cancer cellsSemantic proximity Read

Network integration of thermal proteome profiling with multi-omics data decodes PARP inhibitionSemantic proximity Read

Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of malignant pleural mesotheliomas to CDK4/6 inhibitionSemantic proximity Read

Integration of Thermal Proteome Profiling with phosphoproteomic and transcriptomic data via mechanistic network models decodes the molecular response to PARP inhibitionSemantic proximity Read

MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor ResistanceSemantic proximity Read

Pharmacological CDK4/6 inhibition promotes vulnerability to lysosomotropic agents in breast cancerSemantic proximity Read

Engineered Age-Mimetic Breast Cancer Models Reveal Differential Drug Responses in Young and Aged MicroenvironmentsSemantic proximity Read